Cite
HARVARD Citation
Al-Bakir, M. et al. (2016). An Audit of the Use of Cabazitaxel for the Treatment of Metastatic Castrate Resistant Prostate Cancer (mCRPC) Compared with Previous Experience with ECarboF (Epirubicin, Carboplatin and 5-fluorouracil) in a Single Institution. Clinical oncology. 28 (5), pp. e12-. [Online].